AMPH

#2181
Amphastar Pharmaceuticals, Inc. - Common Stock
18.8 5 USD
+9666.84%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
18.85
18.85
Year Range
0.18
29.52
Daily Change
+9666.84%
Monthly Change
-12.85%
6 month change
-31.30%
Year Change
-22.68%
Previous Close
0.1 9
Open
18.8 5
Low
18.8 5
High
18.8 5
Volume
93
Open full chart Full chart

Financials

Overview Statement Statistics
Quarterly Annual
  • Market Capitalization 831.15 M
  • Employee 1 976
  • Founded 1996
  • CEO N/A
  • Website www.amphastar.com
  • Headquarter California, United States
  • FIGI BBG000BW90S6
  • Industry Drug Manufacturers—Specialty & Generic
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
13.19
Price to sales ratio
1.79

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products. One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally. In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case. In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.

News